MedTrace Logo

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00904579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19929901

Last updated 2020-04-28

No results posted yet for this study

Summary

Background:

* Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression
* End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to transplant, is itself linked to increased risk for some cancers
* The role of immunosuppression and other factors causing cancer in this setting are not fully understood.

Objectives:

* To characterize cancer risk in transplant recipients and identify risk factors.
* To characterize risk for transmission of cancer from organ donors to recipients.
* To describe cancer risk in ESRD.

Eligibility: Patients are not required for this study. Data are gathered from existing databases of ESRD patients, organ transplant patients and cancer registries.

Design:

* Databases of 1) U.S. transplant recipients, donors and wait list candidates and 2) U.S. ESRD patients will be linked to multiple U.S. cancer registries to identify cancers in transplant recipients and ESRD patients.
* The spectrum of cancer risk in transplant recipients and ESRD patients will be evaluated in detail.
* The cancer risk in transplant recipients will be examined in relation to whether the donors had cancer.
* The proposed cancer risk factors (e.g., underlying medical condition, infection with cancer-causing viruses, immunosuppressive medications) documented in transplant and ESRD files will be studied for association with increased risk of particular types of cancer.

Conditions

  • Immunocompromised Host
  • Organ Transplantation
  • Cancer

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Eric A Engels, M.D. · National Cancer Institute (NCI)

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-01
Primary Completion
2020-04-22
Completion
2020-04-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904579 on ClinicalTrials.gov